KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Assets: 2009-2025

Historic Assets for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $3.0 billion.

  • Ionis Pharmaceuticals' Assets fell 1.56% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year decrease of 1.56%. This contributed to the annual value of $3.0 billion for FY2024, which is 0.45% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Assets stood at $3.0 billion for Q3 2025, which was up 1.61% from $3.0 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Assets ranged from a high of $3.1 billion in Q3 2024 and a low of $2.2 billion during Q1 2021.
  • Moreover, its 3-year median value for Assets was $3.0 billion (2023), whereas its average is $2.9 billion.
  • In the last 5 years, Ionis Pharmaceuticals' Assets fell by 27.25% in 2021 and then grew by 21.14% in 2023.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Assets stood at $2.6 billion in 2021, then dropped by 2.98% to $2.5 billion in 2022, then climbed by 18.00% to $3.0 billion in 2023, then increased by 0.45% to $3.0 billion in 2024, then fell by 1.56% to $3.0 billion in 2025.
  • Its last three reported values are $3.0 billion in Q3 2025, $3.0 billion for Q2 2025, and $2.8 billion during Q1 2025.